胰升糖素样肽1受体激动剂与糖尿病、肥胖和银屑病

Glucagon-like peptide-1 receptor agonists, diabetes, obesity, and psoriasis

肠促胰素治疗具有越来越多的胰外作用，最近有病例报道胰升糖素样肽1（GLP-1）受体激动剂治疗能缓解银屑病的临床症状。银屑病是以慢性炎症为特征的常见皮肤病变，流行病学研究发现银屑病患者的心血管疾病、肥胖和糖尿病的发生率增加，这可能与增加的局部和（或）全身的炎症有关。GLP-1受体激动剂可以通过直接或问接的机制影响免疫功能产生抗炎作用，从而改善银屑病症状，这为进一步研究肠促胰素的非经典的抗炎机制提供了新的切入点，同时对拓展GLP-1的临床应用也提供了一个新的研究方向。

More and more extrapancreatic actions of incretin-based therapies have been demonstrated and recently case reports have linked glucagon-like peptide-1 （ GLP-1 ） receptor agonist therapy with the improvements in psoriasis. Psoriasis is a common skin disorder characterized by chronic inflammation. Epideminological studies have showed that patients with psoriasis exhibit increased rates of cardiovascular disease, obesity, and type 2 diabetes, owing probably to the enhanced local and （or） systemic inflammation. The observations of anti-inflammatory actions of GLP-1, which exerts direct and indirect actions on immune function, together with the improved psoriasis, offer new insights into the investigation of non-classical anti-inflammatory actions of incretin-based therapeutics and provide a new direction for the research of the novel clinical application of GLP-1.